Evidence-aware
Safety focused
Women’s Health Clinic FAQ
What are intimate polynucleotides made from?
Intimate polynucleotides are non-hormonal biostimulatory treatments used in some clinics for vulvovaginal tissue quality. The key decision is whether the symptom has been properly assessed first.
Direct answer
Intimate polynucleotides are usually made from highly purified DNA fragments derived from salmon or trout sources, processed to remove proteins and biological debris. Some intimate formulations combine polynucleotides with non-crosslinked hyaluronic acid and mannitol for hydration and stability. The important clinical point is product traceability: the clinic should explain exactly what is being used, why it is suitable and what allergy or infection checks are needed.
The safest plan starts by clarifying the symptom, checking red flags, explaining alternatives and agreeing realistic expectations before any procedure is booked.
Educational only. Suitability must be confirmed after consultation and assessment. Results vary. Not a cure.
At a glance
These are the main points to understand before deciding whether this option is suitable.
Polynucleotides at a glance
Non-hormonal biostimulation
Key points
Composed of medical-grade, sterile fish-derived DNA fragments.
Key point 2
Works by binding to adenosine A2A receptors to stimulate fibroblasts, promoting collagen, elastin, and hyaluronic acid production.
Effects include angiogenesis, anti
inflammation, and deep tissue hydration.
Key point 4
Indicated for GSM, VVA, vaginal dryness, dyspareunia, and itching.
Important safety note
The treatment has an reported safety profile due to the PN-HPT purification process.
Allergy
Technique
Timeline
Aftercare
Detailed answer
How polynucleotides fit into intimate care
Polynucleotides are best explained as biostimulatory DNA fragments rather than fillers. The clinical question is whether they match the diagnosis, tissue findings and safety profile.
Not a standard filler
The aim is gradual tissue-quality support through repair signalling, hydration and extracellular-matrix activity, not instant volume or a promised sexual-function outcome.
Evidence
Symptoms
Alternatives
What it means
Clinical studies consistently show PN therapies effectively reverse morphological signs of VVA, restoring elasticity, pH, and hydration.
Why it happens
It is an especially valuable, safe, and effective treatment for breast cancer survivors suffering from GSM who are contraindicated for hormonal therapies.
Evidence limits
PN is versatile, available as intradermal injections (e.g., NewGyn, Plinest), vaginal ovules, and topical creams.
Treatment fit
Administered primarily via intradermal injections (often combined with hyaluronic acid) using a 30G needle, via linear retrograde infiltration in the labia majora and micro-wheal infiltration in the labia minora.
What this means in practice
Administered primarily via intradermal injections (often combined with hyaluronic acid) using a 30G needle, via linear retrograde infiltration in the labia majora and micro-wheal infiltration in the labia minora.
A standard protocol involves 3 to 5 sessions spaced 2 to 3 weeks apart.
Patient safety
Why diagnosis comes first
Dryness, soreness, tearing or painful sex may reflect GSM, infection, dermatoses, pelvic-floor guarding or medication effects, so the treatment choice depends on assessment.
It checks the cause
Clinical studies consistently show PN therapies effectively reverse morphological signs of VVA, restoring elasticity, pH, and hydration.
It protects safety
The treatment has an reported safety profile due to the PN-HPT purification process.
It reviews alternatives
Administered primarily via intradermal injections (often combined with hyaluronic acid) using a 30G needle, via linear retrograde infiltration in the labia majora and micro-wheal.
It sets expectations
A standard protocol involves 3 to 5 sessions spaced 2 to 3 weeks apart.
Non-hormonal does not mean automatic
A hormone-free treatment may still be unsuitable if there is active infection, unexplained bleeding, pregnancy, recent surgery, severe fish allergy or unclear pelvic pain.
The consultation should cover product source, allergy risk, alternatives such as moisturisers or local hormonal care, and realistic timelines for tissue response.
Considerations
What to consider
Administered primarily via intradermal injections (often combined with hyaluronic acid) using a 30G needle, via linear retrograde infiltration in the labia majora and micro-wheal infiltration in the labia minora.
Consultation priorities
The journey begins with a medical consultation to rule out contraindications like fish allergies.
Consent
Aftercare
Follow-up
Before treatment
The journey begins with a medical consultation to rule out contraindications like fish allergies.
During care
Pre-treatment involves avoiding blood-thinners to reduce bruising.
Aftercare
The procedure takes 30-45 minutes including numbing, involving superficial micro-injections.
When to reassess
Post-care requires avoiding intercourse, tight clothing, and direct friction on the area for a few days, though normal activities can resume immediately.
Practical expectations
A standard protocol involves 3 to 5 sessions spaced 2 to 3 weeks apart.
A topical anaesthetic (e.g., 30% lidocaine gel) is applied 30 minutes prior to ensure patient comfort.
Common concerns and myths
Common misconceptions
Clear patient information should correct over-simple claims and keep expectations realistic.
Myth: polynucleotides are fillers
Reality: they are biostimulatory DNA fragments, usually used for gradual tissue-quality support rather than volume.
Myth: hormone-free means suitable for everyone
Reality: allergy, infection, bleeding, pregnancy, recent surgery and unexplained pain can still make treatment unsuitable.
Myth: hydration means instant repair
Reality: hydration may be noticed earlier, but collagen and tissue-quality changes are gradual and variable.
Evidence and limits
Mechanism-of-action language should not be treated as proof of a predictable clinical result.
Alternatives still matter
Moisturisers, local hormonal care, pelvic-floor physiotherapy, infection treatment or specialist review may be more appropriate for some patients.
Safety checklist
Safety checklist
Use these questions to decide whether treatment should be discussed, delayed or redirected.
Has the cause been assessed?
Symptoms should be reviewed in context before selecting a treatment.
Are red flags absent?
Do not claim intimate polynucleotides cure dryness, laxity, sexual dysfunction, pelvic symptoms, scarring or menopause-related tissue change. Explain that PN products are often fish/marine-derived and allergy history matters.
Are alternatives clear?
Administered primarily via intradermal injections (often combined with hyaluronic acid) using a 30G needle, via linear retrograde infiltration in the labia majora and micro-wheal infiltration in the labia.
Is follow-up planned?
The clinic should explain aftercare, review timing and when to seek help.
Reassuring signs
Proceeding is more reasonable when goals are clear, red flags have been checked, and expectations are realistic.
No red flags
Follow-up plan
Reasons to pause
Pause treatment for active infection, unexplained bleeding, severe fish allergy, pregnancy, recent pelvic surgery or severe pain that has not been assessed.
Bleeding
Infection
When to escalate
When to seek medical help
Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online
Allergy symptoms
Swelling of the lips or tongue, breathing difficulty, widespread hives, faintness or collapse after exposure needs urgent medical help.
Bleeding or infection
New post-menopausal bleeding, unusual discharge, fever, pelvic pain, thrush, BV or UTI symptoms should be assessed before injectable treatment.
Infection signs
Fever, spreading redness, pus or feeling unwell after a procedure needs urgent advice.
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
Regulatory resources
Authoritative resources
These sources support cautious, assessment-led patient information and help separate clinical evidence from promotional claims.
PubMed: PN/HA intradermal injections for vulvovaginal atrophy
This pilot study is directly relevant to polynucleotide and hyaluronic acid use in vulvovaginal atrophy.
Real-world study of polynucleotide-based vaginal ovules
This source supports cautious discussion of PN-based vaginal ovules, hydration and atrophy-related symptoms.
NHS guidance on allergies
NHS allergy guidance supports screening and urgent escalation language for fish-derived products.
Next step
Book a clinical consultation
A consultation can confirm whether this treatment may be suitable, whether another pathway should come first, and what realistic outcomes, risks and aftercare would look like.
▶ View Research Sources (12 Sources)
These 12 source names are selected from 24 display-ready sources, with a raw audit trail of 47 imported records. Additional reviewed material included peer-reviewed clinical papers, evidence reviews, clinical trial records; duplicate, low-relevance and non-clinical records were removed before display.
Educational only. This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Results vary. Not a cure.
